SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cytokine1 who wrote (7029)9/2/1999 11:49:00 PM
From: Vector1  Read Replies (1) of 9719
 
CYTO,
Please add another 500 shares of CELG. The news on Thalomid continues to be good. Today the company reported on a Multiple Myeloma study at Cedars Sinai that showed very postitive results at low doses. The overall response rate was 30% in a group of heavily pre-treated patients who were refactory to chemo. At 7 months 6 of 20 patients showed greater than 50% tumor reduction. One patient had 90% tumor reduction and all patients showed some benefit at 28 days. The drug has already been approved for another indication but CELG will use these studies to gain further market penetration. This stock is a winner.
v1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News